CO5601036A2 - Composicion farmaceutica de liberacion sostenida - Google Patents
Composicion farmaceutica de liberacion sostenidaInfo
- Publication number
- CO5601036A2 CO5601036A2 CO04081686A CO04081686A CO5601036A2 CO 5601036 A2 CO5601036 A2 CO 5601036A2 CO 04081686 A CO04081686 A CO 04081686A CO 04081686 A CO04081686 A CO 04081686A CO 5601036 A2 CO5601036 A2 CO 5601036A2
- Authority
- CO
- Colombia
- Prior art keywords
- sustained release
- support material
- silicone support
- active composition
- release apparatus
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002459 sustained effect Effects 0.000 title 1
- 238000013268 sustained release Methods 0.000 abstract 5
- 239000012730 sustained-release form Substances 0.000 abstract 5
- 239000000463 material Substances 0.000 abstract 4
- 229920001296 polysiloxane Polymers 0.000 abstract 4
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000005426 pharmaceutical component Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
1.- Un aparato de administración de liberación sostenida que incluye un material de soporte de silicona;una composición farmacéuticamente activa transportada en o sobre el material de soporte de silicona;incluyendo la composición farmacéuticamente activa por lo menos un componente farmacéutico asociado con la reproducción y/o el crecimiento; su análogo o su derivado; y un vehículo para el mismo.2.- Un aparato de liberación sostenida de acuerdo con la Reivindicación 1 en donde el aparato exhibe capacidades de carga de activo farmacéutico asociado con la reproducción y/o el crecimiento de aproximadamente 20% a 65% en peso, basado en el peso total de la composición de activo farmacéutico.3.- Un aparato de liberación sostenida de acuerdo con la Reivindicación 2 en donde la capacidad de carga es aproximadamente 30% a 40%.4.- Un aparato de liberación sostenida de acuerdo con la Reivindicación 2, en donde el material de soporte de silicona adopta la forma de una matriz de soporte, tableta o barrita.5.- Un aparato de liberación sostenida de acuerdo con la Reivindicación 4, en donde el material de soporte de silicona tiene una estructura de barrita recubierta.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35144002P | 2002-01-24 | 2002-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5601036A2 true CO5601036A2 (es) | 2006-01-31 |
Family
ID=27613497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO04081686A CO5601036A2 (es) | 2002-01-24 | 2004-08-20 | Composicion farmaceutica de liberacion sostenida |
Country Status (10)
Country | Link |
---|---|
US (2) | US20050025806A1 (es) |
EP (1) | EP1478353A4 (es) |
JP (1) | JP2005522418A (es) |
CN (1) | CN1638747A (es) |
AU (1) | AU2003201410B2 (es) |
BR (1) | BR0307218A (es) |
CA (1) | CA2474292A1 (es) |
CO (1) | CO5601036A2 (es) |
NZ (1) | NZ534317A (es) |
WO (1) | WO2003061634A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW586934B (en) * | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
US20070178454A1 (en) * | 2002-10-21 | 2007-08-02 | Joung J K | Context sensitive paralell optimization of zinc finger dna binding domains |
CN101683317A (zh) * | 2004-05-31 | 2010-03-31 | 斯玛特药物系统公司 | 缓释组合物 |
CA2575988C (en) | 2004-08-04 | 2014-02-18 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
US8133553B2 (en) | 2007-06-18 | 2012-03-13 | Zimmer, Inc. | Process for forming a ceramic layer |
US8309521B2 (en) | 2007-06-19 | 2012-11-13 | Zimmer, Inc. | Spacer with a coating thereon for use with an implant device |
US8608049B2 (en) | 2007-10-10 | 2013-12-17 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
WO2009085952A1 (en) | 2007-12-20 | 2009-07-09 | Brookwood Pharmaceuticals, Inc. | Process for preparing microparticles having a low residual solvent volume |
WO2011037953A2 (en) * | 2009-09-22 | 2011-03-31 | Surmodics Pharmaceuticals, Inc. | Implant devices having varying bioactive agent loading configurations |
AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
CN104655542B (zh) * | 2015-01-05 | 2017-06-20 | 北京市医疗器械检验所 | 一种防护产品检测用合成血液及其配制方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4351337A (en) * | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
US4326524A (en) * | 1980-09-30 | 1982-04-27 | Minnesota Mining And Manufacturing Company | Solid dose ballistic projectile |
US5989579A (en) * | 1986-10-02 | 1999-11-23 | Escalon Medical Corp. | Ocular insert with anchoring protrusions |
ATE86484T1 (de) * | 1987-08-08 | 1993-03-15 | Akzo Nv | Kontrazeptives implantat. |
US5035891A (en) * | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
US5141748A (en) * | 1989-02-17 | 1992-08-25 | Hoffmann-La Roche, Inc. | Implant drug delivery device |
US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
JP3720386B2 (ja) * | 1993-12-27 | 2005-11-24 | 住友製薬株式会社 | 薬物放出制御製剤 |
AU716005B2 (en) * | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
AU744727B2 (en) * | 1997-07-21 | 2002-02-28 | Vantico Ag | Sedimentation stabilized radiation-curable filled compositions |
US6028057A (en) * | 1998-02-19 | 2000-02-22 | Thorn Bioscience, Llc | Regulation of estrus and ovulation in gilts |
US6274159B1 (en) * | 1998-10-28 | 2001-08-14 | University Of Florida | Surface modified silicone drug depot |
US20020131988A1 (en) * | 1999-12-16 | 2002-09-19 | Foster Todd P. | Pharmaceutical implant containing immediate-release and sustained-release components and method of administration |
AUPR602501A0 (en) * | 2001-06-29 | 2001-07-26 | Smart Drug Systems Inc | Sustained release pharmaceutical composition |
AUPR951501A0 (en) * | 2001-12-14 | 2002-01-24 | Smart Drug Systems Inc | Modified sustained release pharmaceutical system |
-
2003
- 2003-01-23 NZ NZ534317A patent/NZ534317A/en not_active IP Right Cessation
- 2003-01-23 WO PCT/AU2003/000071 patent/WO2003061634A1/en active Application Filing
- 2003-01-23 CN CNA038045605A patent/CN1638747A/zh active Pending
- 2003-01-23 AU AU2003201410A patent/AU2003201410B2/en not_active Ceased
- 2003-01-23 EP EP03700100A patent/EP1478353A4/en not_active Withdrawn
- 2003-01-23 JP JP2003561579A patent/JP2005522418A/ja not_active Withdrawn
- 2003-01-23 BR BR0307218-5A patent/BR0307218A/pt not_active IP Right Cessation
- 2003-01-23 CA CA002474292A patent/CA2474292A1/en not_active Abandoned
-
2004
- 2004-07-22 US US10/895,957 patent/US20050025806A1/en not_active Abandoned
- 2004-08-20 CO CO04081686A patent/CO5601036A2/es not_active Application Discontinuation
-
2006
- 2006-02-02 US US11/345,364 patent/US20060246110A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1478353A4 (en) | 2007-10-17 |
CN1638747A (zh) | 2005-07-13 |
CA2474292A1 (en) | 2003-07-31 |
WO2003061634A1 (en) | 2003-07-31 |
JP2005522418A (ja) | 2005-07-28 |
US20050025806A1 (en) | 2005-02-03 |
EP1478353A1 (en) | 2004-11-24 |
AU2003201410B2 (en) | 2008-07-03 |
BR0307218A (pt) | 2004-12-07 |
NZ534317A (en) | 2006-06-30 |
US20060246110A1 (en) | 2006-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5560533A2 (es) | Preparacion de una composicion farmaceutica de liberacion sostenida | |
CO5601036A2 (es) | Composicion farmaceutica de liberacion sostenida | |
CO5540373A2 (es) | Composicion farmaceutica de liberacion sostenida | |
ES2172195T3 (es) | Inhibicion de la cristalizacion en dispositivos transdermales. | |
AR039335A1 (es) | Tableta de carga de droga alta | |
ATE251449T1 (de) | Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe | |
ES2195308T3 (es) | Composicon farmaceutica de fenofibrato que presenta una biodisponibilidad elevada, y metodo para su preparacion. | |
CL2008002407A1 (es) | Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04). | |
MX2010004366A (es) | Materiales inmiscibles en agua como vehiculos para suministro de farmacos. | |
ES2125848T1 (es) | Comprimidos bioadhesivos. | |
BR0316564A (pt) | Forma de dosagem de alérgeno | |
ECSP088106A (es) | Formas de dosificación de liberación retardada oral altamente biodisponible del succinato de o-desmetilvenlafaxina | |
CL2008000823A1 (es) | Formulacion farmaceutica de liberacion inmediata que comprende dapagliflozina propilenglicol hidrato y un portador farmaceuticamente aceptable; uso para tratar diabetes, intolerancia a la glucosa, resistencia a la insulina, entre otras. | |
PE20080907A1 (es) | Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan | |
CO6260045A2 (es) | Sistema de suministro de farmaco que comprende por lo menos un compartimento con una capa de nucleo de polimero termoplastica cargada con farmaco, una capa intermedia de polimero termoplastica cargada con farmaco y una piel de polimero termoplastica | |
ECSP10010416A (es) | Forma de dosificación farmaceutica | |
AR063958A1 (es) | Metodos para administrar medicaciones para la perdida de peso | |
AR024228A1 (es) | Una composicion farmaceutica que comprende un sensibilizador de insulina y otro agente antidiabetico | |
AR061102A1 (es) | Sistemas de suministro de perfume para bienes de consumo | |
DE60205749D1 (de) | Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe | |
DE602006016127D1 (de) | Zusammensetzung und dosierform mit einer festen oder halbfesten matrix | |
AR057932A1 (es) | Comprimido bicapa que comprende telmisartan y diuretico | |
CL2008003024A1 (es) | Compuestos derivados de alquilsulfonilbenzotiazol, moduladores del receptor de grelina; formulacion farmaceutica; y uso para el tratamiento de obesidad o sobrepeso, diabetes, sindrome metabolico, entre otras. | |
DE602004023093D1 (de) | N mit einem abgabemittel in mikronisierter form | |
EA200700217A1 (ru) | Фармацевтическая композиция в форме таблетки для нахождения в желудке, содержащая активное вещество |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |